Virginia Tech® home

Archived Virtual Seminar: IL-1 blockade in heart disease

Special Seminar presented by the Center for Vascular and Heart Research and the Fralin Biomedical Research Institute at VTC

IL-1 blockade in heart disease

Date: May 13, 2021
Time: 11:00 a.m. - 12:00 p.m.

About this Seminar

The intracellular sensing protein termed NLRP3 (for NACHT, LRR, and PYD domains-containing protein 3) forms a macromolecular structure called the NLRP3 inflammasome. The NLRP3 inflammasome plays a major role in inflammation, particular in the production of interleukin-1b (IL-1b). IL-1b is the most studied of the IL-1 family of cytokines, including 11 members among which IL-1a and IL-18.  Dr. Abbate will summarize pre-clinical and clinical findings supporting the key pathogenetic role of the NLRP3 inflammasome and IL-1 cytokines in the formation, progression and complications of atherosclerosis, in ischemic (acute myocardial infarction, AMI), and non-ischemic injury to the myocardium (myocarditis)  and the progression to heart failure (HF).  He will also review the clinically available IL-1 inhibitors, although not currently approved for a cardiovascular indications, and discuss other IL-1 inhibitors, not currently approved, as well as oral NLRP3 inflammasome inhibitors currently in clinical development. Canakinumab, IL‑1b  antibody, prevented the recurrence of ischemic events in patients with prior AMI in a large phase III clinical trial including 10,061 patients world-wide. Phase II clinical trials show promising data with anakinra, recombinant IL-1 receptor antagonist, in patients with ST segment elevation AMI or HF with reduced ejection fraction. Anakinra also improved outcomes in patients with pericarditis and it is now considered standard of care as second line treatment for patients with recurrent/refractory pericarditis. Rilonacept, a soluble IL‑1 receptor chimeric fusion protein neutralizing IL-1aand IL-1b, has also shown promising results in a phase II study in recurrent/ refractory pericarditis. In conclusion, there is overwhelming evidence linking the NLRP3 inflammasome and the IL-1 cytokines with the pathogenesis of cardiovascular diseases. The future will likely include targeted inhibitors to block the IL‑1 isoforms, and possibly oral NLRP3 inflammasome inhibitors, across a wide spectrum of cardiovascular diseases.

 

You May Also Be Interested In...

  • Home Item
    Inheriting Chromatin Domains in Mammals and the Mechanisms Involved , home

    Sept. 5, 2025, 11:00 a.m. | Thelma Escobar, Ph.D., Assistant Professor, Department of Biochemistry, Institute for Stem Cell & Regenerative Medicine, University of Washington | Co-Sponsored by the Fralin Biomedical Research Institute and Cancer Research Center — D.C.

  • Home Item
    Flow Induced Endothelial Planar Polarity for Signaling Regulation , home

    Sept. 19, 2025, 11:00 a.m. | Julia Mack, Ph.D., Assistant Adjunct Professor, David Geffen School of Medicine, Division of Cardiology, University of California Los Angeles | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research

  • Home Item
    Maury Strauss Distinguished Public Lecture , home

    Sept. 18, 2025, 5:30 p.m. (Reception at 5 p.m.) | Robert Gourdie, Ph.D., FAHA, AIMBE, Heywood Fralin Professor and Director, Center for Vascular and Heart Research, Fralin Biomedical Research Institute; Professor, Department of Biomedical Engineering and Mechanics, Virginia Tech College of Engineering; Elected Member, National Academy of Inventors | Maury Strauss Distinguished Public Lecture

  • Home Item
    The Bitter Truth: Alcohol Use and Its Effects on Chemosensory Function , home

    Oct. 3, 2025, 11:00 a.m. | Paule Valery Joseph, Ph.D., Lasker Clinical Research Scholar, NIH Distinguished Scholar; Acting Chief, Section of Sensory Science and Metabolism Unit, Co-Director of the National Smell and Taste Center, National Institute on Deafness and Other Communication Disorders; National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health | Co-Sponsored by the Fralin Biomedical Research Institute Center for Health Behaviors Research and Addiction Recovery Research Center

  • Home Item
    Organization and Control of Hippocampal Networks , home

    Oct. 17, 2025, 11:00 a.m. | Ivan Soltesz, Ph.D., James R. Doty Professor of Neurosurgery and Neurosciences, Stanford University | Co-Sponsored by the Fralin Biomedical Research Institute Center for Neurobiology Research

Antonio Abbate, M.D., Ph.D.

Antonio Abbate, M.D., Ph.D.

James C. Roberts, Esq., Professor of Cardiology, Department of Internal Medicine, Division of Cardiology, VCU Pauley Heart Center;  and Professor, Department of Internal Medicine and Department of Physiology and Biophysics, Virginia Commonwealth University